Skip to main content
SpringerLink
Log in

Disease Course and Prognosis

  • Chapter
  • First Online:
Cannabis in Psychiatric Practice

Part of the book series: Psychiatry Update ((PU,volume 3))

  • 433 Accesses

Abstract

Within the last decade, there has been a rapid shift in the legal status, and arguably the public perception, of cannabis. Inevitably then, in most clinical psychiatry practice, patients and providers may wish to discuss cannabis use as it relates to mental health. Arguably the best data to support a clinician’s stance on marijuana use can be found in longitudinal studies meant to compare outcomes in those who do and do not use cannabis, with similar psychiatric conditions. In this chapter we aim to distill the most pertinent of this data, such that it can be accessible to patients as well as providers, and also to give practical advice from guidelines and our own practices on managing these discussions. Finally, we attempt to balance negative outcomes data with discussion of potential but limited studies evaluating benefits from cannabinoids more generally.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. National Academies of Sciences Engineering and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on the Health Effects of Marijuana: an Evidence Review and Research Agenda. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: National Academies Press; 2017. https://doi.org/10.17226/24625.

  2. Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in South London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2(3):233–8. https://doi.org/10.1016/S2215-0366(14)00117-5.

    Article  PubMed  Google Scholar 

  3. Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427–36. https://doi.org/10.1016/S2215-0366(19)30048-3.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Starzer MSK, Nordentoft M, Hjorthøj C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry. 2018;175(4):343–50. https://doi.org/10.1176/appi.ajp.2017.17020223.

    Article  PubMed  Google Scholar 

  5. Donoghue K, Doody GA. Effect of illegal substance use on cognitive function in individuals with a psychotic disorder: a review and meta-analysis. Neuropsychology. 2012;26(6):785–801. https://doi.org/10.1037/a0029685.

    Article  PubMed  Google Scholar 

  6. Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015;171:39–47. https://doi.org/10.1016/j.jad.2014.09.016.

    Article  PubMed  Google Scholar 

  7. Feingold D, Weiser M, Rehm J, Lev-Ran S. The association between cannabis use and mood disorders: a longitudinal study. J Affect Disord. 2015;172:211–8. https://doi.org/10.1016/j.jad.2014.10.006.

    Article  PubMed  Google Scholar 

  8. Pinto JV, Medeiros LS, Santana da Rosa G, Santana de Oliveira CE, de Souza Crippa JA, Passos IC, et al. The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: a systematic review with meta-analysis and meta-regression. Neurosci Biobehav Rev. 2019;101:78–84. https://doi.org/10.1016/j.neubiorev.2019.04.004.

    Article  PubMed  Google Scholar 

  9. Zorrilla I, Aguado J, Haro JM, Barbeito S, López Zurbano S, Ortiz A, et al. Cannabis and bipolar disorder: does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes? Acta Psychiatr Scand. 2015;131(2):100–10. https://doi.org/10.1111/acps.12366.

    Article  CAS  PubMed  Google Scholar 

  10. Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. Psychiatry Res. 2013;209(3):459–65. https://doi.org/10.1016/j.psychres.2012.12.014.

    Article  PubMed  Google Scholar 

  11. Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiat. 2018;75(4):336–46. https://doi.org/10.1001/jamapsychiatry.2017.4602.

    Article  Google Scholar 

  12. Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2014;44(4):797–810. https://doi.org/10.1017/S0033291713001438.

    Article  CAS  PubMed  Google Scholar 

  13. Feingold D, Rehm J, Lev-Ran S. Cannabis use and the course and outcome of major depressive disorder: a population based longitudinal study. Psychiatry Res. 2017;251:225–34. https://doi.org/10.1016/j.psychres.2017.02.027.

    Article  PubMed  Google Scholar 

  14. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States: anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169–84. https://doi.org/10.1002/mpr.1359.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Hser Y-I, Mooney LJ, Huang D, Zhu Y, Tomko RL, McClure E, et al. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abus Treat. 2017;81:53–8. https://doi.org/10.1016/j.jsat.2017.07.012.

    Article  Google Scholar 

  16. Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies. BMC Psychiatry. 2014;14:136. https://doi.org/10.1186/1471-244X-14-136.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Botsford SL, Yang S, George TP. Cannabis and cannabinoids in mood and anxiety disorders: impact on illness onset and course, and assessment of therapeutic potential. Am J Addict. 2020;29(1):9–26. https://doi.org/10.1111/ajad.12963.

    Article  PubMed  Google Scholar 

  18. Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76(09):1174–80. https://doi.org/10.4088/JCP.14m09475.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Carpentier PJ, Levin FR. Pharmacological treatment of ADHD in addicted patients: what does the literature tell us? Harv Rev Psychiatry. 2017;25(2):50–64. https://doi.org/10.1097/HRP.0000000000000122.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Notzon DP, Pavlicova M, Glass A, Mariani JJ, Mahony AL, Brooks DJ, Levin FR. ADHD is highly prevalent in patients seeking treatment for cannabis use disorders. J Atten Disord. 2020;24(11):1487–92. https://doi.org/10.1177/1087054716640109.

    Article  PubMed  Google Scholar 

  21. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73. https://doi.org/10.1001/jama.2015.6358.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, UCHealth Medical Center of the Rockies, University of Colorado School of Medicine, Fort Collins, CO, USA

    Matthew Shirazi

  2. Department of Psychiatry, University of Colorado School of Medicine, Aurora, CO, USA

    David Riedford

Authors
  1. Matthew Shirazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Riedford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew Shirazi .

Editor information

Editors and Affiliations

  1. Department of Psychiatry, University of Colorado School of Medicine, Aurora, CO, USA

    Paula Riggs

  2. Department of Psychiatry, University of Colorado School of Medicine, Aurora, CO, USA

    Thida Thant

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shirazi, M., Riedford, D. (2022). Disease Course and Prognosis. In: Riggs, P., Thant, T. (eds) Cannabis in Psychiatric Practice. Psychiatry Update, vol 3. Springer, Cham. https://doi.org/10.1007/978-3-031-04874-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-04874-6_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-04873-9

  • Online ISBN: 978-3-031-04874-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation